EATG » Hepatitis

Hepatitis

EGALITE study confirms efficacy of elbasvir/grazoprevir for patients with HCV, mild fibrosis

Results from the EGALITE study showed that 12 weeks of elbasvir/grazoprevir was a highly effective regimen for treatment-naive Asian patients with hepatitis C virus genotype 1b infection and mild liver…

Approximately 12 million ROL allocated to the National Framework Plan for Viral Hepatitis Control in Romania for the period 2019-2030

The Ministry of Health (MoH) launched the National Framework Plan for Viral Hepatitis Control in Romania for the period 2019-2030. It aims to reduce the prevalence of viral hepatitis as…

Access to hepatitis C testing and treatment for people who inject drugs and people in prisons — a global perspective

The World Health Organization (WHO) released a policy brief on access to HCV testing and treatment for people who inject drugs and for people in prisons (April 2019). Overview WHO…

Worse Outcomes for Patients Not Achieving Sustained Viral Remission After HCV Treatment

Patients who do not achieve sustained viral remission (SVR) after completing direct-acting antiviral treatment for hepatitis C virus (HCV) infection experience worsening health-related quality of life (HRQoL), according to a…

New progress in developing an animal model of hepatitis C

Small differences in a liver cell protein have significant impacts on hepatitis C virus replication in mice and humans, findings that could facilitate the development of a mouse model of…

Cash incentives, peer support may not incentivize HCV treatment

A randomized trial comparing a cash incentive to peer support for increasing acceptance of treatment for hepatitis C virus (HCV) among persons with HCV/HIV coinfection, including those who use drugs or alcohol,…

Needleless vaccine will protect children from dangerous viruses

Orally administered vaccine can protect millions from hepatitis B. Oral vaccines are both safer and less expensive than injections; researchers are continuously pursuing ways to produce an oral vaccine that…

Dynavax announces first patient enrolled in study of HEPLISAV-B® in adults with end-stage renal disease

Trial to evaluate immunogenicity and safety of Hepatitis B vaccine, HEPLISAV-B, in patients with end-stage renal disease who are initiating or undergoing dialysis BERKELEY, Calif., May 02, 2019 -- Dynavax…

World Health Organization calls for greater focus on people who inject drugs in HCV treatment scale-up plans

The World Health Organization (WHO) has called for greater commitments to scale up hepatitis C virus (HCV) testing and treatment services to people who inject drugs (PWID) and people in…

FDA approves first treatment for all genotypes of hepatitis C in pediatric patients

The U.S. Food and Drug Administration today (April 30) approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to…